Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
2008
Abstract
Recent studies have demonstrated that combined substitutions of rifapentine for rifampin and moxifloxacin for isoniazid in the standard, daily, short-course regimen of rifampin, isoniazid, and pyrazinamide produces stable cure in 12 weeks or less. This study was designed to more precisely evaluate the contribution of moxifloxacin and isoniazid to rifapentine-based regimens.
Details
Title
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Author(s)
Rosenthal, Ian M. ; Zhang, Ming ; Almeida, Deepak ; Grosset, Jacques H. ; Nuermberger, Eric L.
Published in
American journal of respiratory and critical care medicine
Volume
178
Issue
9
Pages
989-93
Date
2008
ISSN
1535-4970
Laboratories
GHI
Record Appears in
Scientific production and competences > SV - School of Life Sciences > GHI - Global Health Institute > UNATTRIBUTED-GHI - GHI - Unattributed publications
Work produced at EPFL
Journal Articles
Published
Work produced at EPFL
Journal Articles
Published
Record creation date
2012-04-27